BRISTOL-MYERS SQUIBB and Celldex Therapeutics Inc. entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, BMS’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a phase I/II study.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
